N-Butyl-N-(3-Chloropropyl)Butan-1-Amine as a Key Dronedarone Intermediate: Technical and Commercial Insights
- Serves as the essential alkylating agent in the multi-step synthesis of dronedarone hydrochloride, a Class III antiarrhythmic drug.
- Manufactured via high-yield chlorination of 3-(dibutylamino)propan-1-ol, achieving >94% reaction efficiency under optimized conditions.
- NINGBO INNO PHARMCHEM CO.,LTD. supplies bulk quantities with industrial purity ≥98%, supported by full COA and regulatory documentation.
In the pharmaceutical manufacturing landscape, N-Butyl-N-(3-chloropropyl)butan-1-amine—more systematically known as N-(3-chloropropyl)dibutylamine (CAS 36421-15-5)—plays a pivotal role as a chemical intermediate in the synthesis of dronedarone hydrochloride. Marketed under the brand Multaq®, dronedarone is a benzofuran-derived antiarrhythmic agent developed to mimic the electrophysiological effects of amiodarone while reducing systemic toxicity. The structural integrity and purity of this intermediate directly influence the quality, yield, and impurity profile of the final active pharmaceutical ingredient (API).
Role in Dronedarone Hydrochloride Synthesis
The synthesis of dronedarone begins with the alkylation of a substituted phenol (typically 2-butyl-3-(4-hydroxy-3,5-diiodophenyl)benzofuran) using N,N-dibutyl-3-chloro-1-propanamine as the alkylating reagent. This step forms a key ether-linked intermediate that undergoes subsequent hydrogenation and methanesulfonylation to yield dronedarone free base, which is then isolated as the hydrochloride salt.
Critical to this process is the reactivity and steric accessibility of the chloropropyl group in 3-chloropropyl dibutylamine. Impurities such as N-(3-chloropropyl)butan-1-amine or 3-chloropropan-1-amine—resulting from incomplete butylation during synthesis—can lead to monoalkylated byproducts like debutyldronedarone (a known metabolite and potential process-related impurity). Therefore, stringent control over the industrial purity of the intermediate is non-negotiable for GMP-compliant API production.
Synthesis Route and Reaction Yield Optimization
The standard synthesis route for N-(3-chloropropyl)dibutylamine involves the chlorination of 3-(dibutylamino)propan-1-ol using thionyl chloride (SOCl₂) under reflux in an inert solvent like chloroform. A representative procedure yields 94% of the target compound as a pale yellow liquid after aqueous workup and drying:
- Starting material: 3-(Dibutylamino)propan-1-ol (0.418 g, 2.23 mmol)
- Chlorinating agent: Thionyl chloride (0.328 mL, 4.46 mmol)
- Reaction time/temp: 7 hours under reflux
- Workup: Neutralization with K₂CO₃, extraction with CH₂Cl₂, drying (MgSO₄), solvent evaporation
- Yield: 0.430 g (94%) of dibutyl(3-chloropropyl)amine
This high-yield transformation is scalable and compatible with continuous-flow or batch manufacturing, making it ideal for commercial API production. NINGBO INNO PHARMCHEM CO.,LTD. has refined this process to ensure consistent output with minimal residual solvents or unreacted precursors.
Technical Specifications and Quality Assurance
For pharmaceutical applications, the following specifications are typically required for N-(3-chloropropyl)dibutylamine:
| Property | Value |
|---|---|
| Molecular Formula | C₁₁H₂₄ClN |
| Molecular Weight | 205.77 g/mol |
| Appearance | Pale yellow liquid |
| Boiling Point | 118–130 °C @ 25 Torr |
| Density | 0.899 ± 0.06 g/cm³ (predicted) |
| pKa | 9.39 ± 0.50 (predicted) |
| Storage Condition | 2–8 °C, under inert atmosphere |
| Typical Purity (GC/HPLC) | ≥98% |
Every batch supplied by NINGBO INNO PHARMCHEM CO.,LTD. is accompanied by a Certificate of Analysis (COA), including GC chromatograms, NMR validation data, and residual solvent reports. This ensures seamless integration into regulated pharmaceutical workflows and compliance with ICH Q3 guidelines on impurities.
Bulk Procurement and Global Supply Chain
As a premier global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. offers N-(3-chloropropyl)dibutylamine in bulk quantities (from 1 kg to multi-ton scale) with flexible packaging and rapid global logistics. Competitive bulk price structures are available for long-term partnerships, with supply capacity exceeding 30 metric tons per month.
When sourcing high-purity pharmaceutical intermediate materials for antiarrhythmic drug synthesis, buyers prioritize not only cost but also reliability, documentation, and technical support. NINGBO INNO PHARMCHEM CO.,LTD. meets these demands through ISO-certified facilities, DMF filings, and dedicated R&D teams focused on optimizing the manufacturing process for complex amines like this dronedarone precursor.
Safety and Handling Considerations
Due to its classification under GHS08 (health hazard), N-(3-chloropropyl)dibutylamine requires careful handling. Hazard statements include H315 (skin irritation), H319 (eye irritation), H372 (organ toxicity with prolonged exposure), and H350 (suspected carcinogen). Users must adhere to precautionary measures such as wearing chemical-resistant gloves (P280), using respiratory protection in poorly ventilated areas (P284), and avoiding ingestion or inhalation (P260, P270).
Storage at 2–8 °C in tightly sealed containers under nitrogen minimizes degradation and maintains stability over extended periods—critical for inventory management in large-scale API campaigns.
Conclusion
N-Butyl-N-(3-chloropropyl)butan-1-amine remains indispensable in the efficient, high-fidelity production of dronedarone hydrochloride. Its role as a well-defined chemical intermediate hinges on precise synthesis control, rigorous purity standards, and reliable supply. Among global suppliers, NINGBO INNO PHARMCHEM CO.,LTD. stands out for its technical excellence, scalable infrastructure, and commitment to pharmaceutical-grade quality—making it the partner of choice for innovator and generic drug manufacturers alike.